| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
Department of Internal Medicine (M.B.), Division of Endocrinology, University of Ancona, 60100 Ancona, Italy; and Department of Medical and Surgical Sciences, Division of Endocrinology (N.S., A.S., L.B., F.F.), and Second Chair of Medicine (M.T.S., G.M.P., A.G.), University of Padova, 35128 Padova, Italy
Address all correspondence and requests for reprints to: Marco Boscaro, M.D., Department of Internal Medicine, Division of Endocrinology, University of Ancona, 60100 Torrette, Ancona, Italy. E-mail: . m.boscaro{at}ao-umbertoprimo.marche.it
Abstract
A hypercoagulable state and an increased incidence of thromboembolic complications are reported in Cushings syndrome. The hypercoagulable state is related to an increase in plasma clotting factors, especially Factor VIII and von Willebrand factor complex, and to an impairment of fibrinolytic capacity. Retrospective analysis of postoperative thromboembolic events in a large group of patients with Cushings syndrome, including 75 patients (group 1) evaluated in the period from 19721981 not receiving anticoagulants, and 232 patients (group 2), evaluated in the period from 19822000. Patients of group 1 underwent routine hemostatic function, i.e. prothrombin time and activated partial thromboplastine time. Patients of group 2 underwent a thorough investigation as to hemostatic parameters and received prophylactic treatment with heparin and/or warfarin. Patients with Cushings syndrome showed various abnormalities of hemostatic parameters. A significant correlation between activated partial thromboplastine time and urinary free cortisol was observed. During follow-up, 15 patients (20%; mean follow-up, 9.4 ± 6.4 yr) of group 1 and 14 (6.0%; mean follow-up, 6.6 ± 4.2 yr) of group 2 showed thromboembolic complications. Of these patients, eight of group 1 and one of group 2 died. Survival analysis demonstrated a significantly higher morbidity and mortality due to thromboembolic events in group 1, not receiving anticoagulant prevention, than in group 2, treated with anticoagulants in the perioperative period until cure of the disease and normalization of clotting parameters. Cushings syndrome is associated with a hypercoagulable state. An adequate anticoagulant prophylaxis can reverse this prothrombotic state and avoid postoperative thromboembolic events.
This article has been cited by other articles:
![]() |
M. Terzolo, B. Allasino, S. Bosio, E. Brusa, F. Daffara, M. Ventura, E. Aroasio, G. Sacchetto, G. Reimondo, A. Angeli, et al. Hyperhomocysteinemia in Patients with Cushing's Syndrome J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3745 - 3751. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ilias, R. Chang, K. Pacak, E. H. Oldfield, R. Wesley, J. Doppman, and L. K. Nieman Jugular Venous Sampling: An Alternative to Petrosal Sinus Sampling for the Diagnostic Evaluation of Adrenocorticotropic Hormone-Dependent Cushing's Syndrome J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3795 - 3800. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Arnaldi, A. Angeli, A. B. Atkinson, X. Bertagna, F. Cavagnini, G. P. Chrousos, G. A. Fava, J. W. Findling, R. C. Gaillard, A. B. Grossman, et al. Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5593 - 5602. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |